Obstetric Delivery
Novo Nordisk and NanoVation Collaborate on $600M Genetic Medicine Deal for Rare and Cardiometabolic Diseases
Novo Nordisk, NanoVation, genetic medicine, lipid nanoparticle technology, cardiometabolic diseases, rare diseases, RNA delivery, base-editing therapies
Gene editing delivery biotech GenEdit partners with Genentech, raises another $24M
genentech, GenEdit, Gene Modification, Obstetric Delivery